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Objectives: World Health Organization (WHO) guidelines for health programmes and healthcare delivery
are the foundation of its technical leadership in public health and essential to decision-making globally. A
key function of guideline development is to identify areas in which further evidence is needed because
filling these gaps will lead to future improvements in population health. The objective of this study was
to examine the knowledge gaps and research questions for addressing those gaps generated through the
WHO guideline development process, with the goal of informing future strategies for improving and
strengthening the guideline development process.
Study design: We did a systematic, retrospective analysis of research questions identified in the pub-
lished guidelines.
Methods: We analyzed guidelines published between January 1, 2008, and December 31, 2018, by the
Communicable Diseases Cluster in five disease areas: tuberculosis (TB), HIV, malaria, TB-HIV, and
neglected tropical diseases (NTDs). Research questions were extracted independently by two researchers.
We analyzed the distribution of research questions by disease and by topic category and did a qualitative
assessment of optimum practice for research question generation during the guideline development
process.
Results: A total of 48 guidelines were included: 26 on HIV, 1 on malaria, 11 on TB, 5 on TB/HIV, and 5 on
NTDs. Overall, 36 (75%) guidelines encompassed a total of 360 explicit research questions; the remainder
did not contain specific research questions. The number of research questions that focused on TB was 49,
TB/HIV was 38, HIV was 250, and NTDs was 23. The number of research questions that focused on
diagnosis was 43 (11.9%) of 360, prevention was 62 (17.2%), treatment was 103 (28.6%), good practice was
12 (3.3%), service delivery was 86 (23.8%), and other areas was 54 (15%). Research questions were often
not formulated in a specific or actionable way and were hard to identify in the guideline. Examples of
good practice identified by the review team involved the generation of specific and narrowly defined
research questions, with accompanying recommendations for appropriate study design.
Conclusions: The WHO must strengthen its approach to identifying and presenting research questions
during the guideline development process. Ensuring access to research questions is a key next step in
adding value to the guideline development process.
© 2020 Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access
article under the CC BY-NC-ND IGO license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).of The Royal Society for Public HeaIntroduction
One of the most important normative roles of the World Health
Organization (WHO) is to develop guidelines for health pro-
grammes to support best practice in healthcare delivery. Producinglth. This is an open access article under the CC BY-NC-ND IGO license (http://creative
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nosis, management, and treatment, in support of evidence-based
approaches to the prevention and control of diseases.1e4 WHO
guidelines aim to promote the achievement of the Sustainable
Development Goals and access to universal health coverage and
reflect the core WHO value of the ‘right to health.’3,4
The WHO and other national and international guideline
development groups strive to ensure that their guidelines meet the
highest international standards and are impactful at the country
level. In 2007, the WHO Guidelines Review Committee (GRC) was
established to oversee the processes and methods used to develop
WHO guidelines and to ensure the quality of all published guide-
lines. The GRC re-established a set of guideline development
standards and adopted the GRADE (Grading of Recommendations
Assessment, Development and Evaluation) approach in formulating
evidence-based recommendations.5 The guideline development
process involves carrying out systematic reviews of the evidence
for each of the key questions underpinning recommendations in a
guideline, with assessment of the quality or certainty of the body of
evidence, and the explicit and transparent formulation of recom-
mendations based on the balance of benefits and harms of an
intervention and other important considerations such as accept-
ability, resource use, and effects on equity. In addition, guideline
development groups should formulate research questions needed
to address identified gaps in knowledge.6,7
There has been significant improvement within the WHO in
developing public health guidelines.8,9 However, there has been
little emphasis on the opportunity provided by the guideline
development process to identify, formulate, and compile relevant
research questions that address knowledge gaps. This approach has
been promoted for informing the development of a public health
research agenda for theWHO.6,7 Since 2014, theWHO Handbook for
Guideline Development has included the following advice: ‘When
gaps in the evidence are such that significant uncertainty exists
with respect to the balance of an intervention's benefits and harms,
such knowledge gaps should be described and questions and
methods for addressing the gaps should be suggested.’4 Answering
the research questions identified through the guideline develop-
ment process fills knowledge gaps directly relevant to programmes
and contributes to improved delivery of interventions and better
health. Systematically compiling and disseminating the research
questions identified through the WHO guideline development
process can therefore help maximize public health relevance of
future research.7,10,11,12
For a selected set ofWHO guidelines, i.e., those developed by the
WHO Communicable Diseases Cluster on tuberculosis (TB), HIV,
malaria, TB-HIV, and neglected tropical diseases (NTDs) between
2008 and 2018, we therefore assessed the extent to which the
guideline development process identifies research questions that
address knowledge gaps. The objective of this study was to
examine the research questions generated through the WHO
guideline development process with the goal of informing future
strategies for improving and collating these questions into an open-
access online directory.
Methods
Inclusion and exclusion criteria
Wedid a systematic, retrospective analysis of research questions
contained in all WHO guidelines approved by the GRC and pub-
lished between January 1, 2008, and December 31, 2018, by the CDS
at WHO headquarters in Geneva, Switzerland. This unit produces
guidelines on TB, HIV, malaria, TB-HIV, and NTDs. A research
question was defined as an answerable or actionable enquirygenerated through the guideline development process describing
an identified knowledge gap or where it was explicitly stated in the
guideline to be a research question.
The GRC Secretariat provided a database containing all WHO
guidelines published during the relevant time period. From this
database, we identified guidelines related to the five disease areas
of interest (TB, HIV, malaria, TB-HIV, and NTDs). The most recent
guidelines were used when multiple guidelines were available on
the same topic.
Data extraction
Research questions were extracted from the published guideline
documents independently and in duplicate by J.H. and S.H. This
involved a systematic search of the guideline for the following
terms: research, research questions, research gaps, research needs,
research priorities, knowledge gaps, outstanding research, quality
of evidence, and implications of research. Research questions were
extracted verbatim into an Excel file and assigned to the relevant
disease area. Where research questions were present in paragraphs
of text pertaining to research gaps or research questions, we dis-
aggregated the text into separate research questions, wherever
possible.
Analysis and validation
We categorized research questions into six broad areas: diag-
nosis, prevention, treatment, specific procedural/operational needs
to establish good practice, service delivery, and ‘other.’Once all data
had been extracted from the guidelines and categorized, we
analyzed the number of guidelines for each disease and the dis-
tribution of research questions by disease grouping and by topic
area. We did a qualitative assessment of optimum approaches for
defining actionable research questions, which involved two re-
searchers doing an in-depth reading of all included guidelines to
explore areas of good and bad practice in the generation of research
questions and knowledge gaps during the guideline development
process. The researchers took detailed notes during the process,
whichwere discussed during a face-to-face review teammeeting to
agree on optimum approaches, to inform the guideline develop-
ment process going forward.
Because we planned to use the identified research questions to
populate an open-access online directory, identified research
questions underwent an internal validation process by senior WHO
technical staff with responsibility for each of the five disease areas
under study to assess which research questions were still relevant
to the current disease context. An Excel (Microsoft, Redmond, WA,
USA) spreadsheet of research questions identified from the guide-
lines was sent via email to each of the staff members who then
coordinated a discussion within their department to assess which
research questions were still relevant. Irrelevant and outdated
questions were removed.
Results
Distribution of guidelines and research questions by disease
A total of 48 guidelines were included in total (2008e2018),
including 26 on HIV, 1 on malaria, 11 on TB, 5 on TB-HIV, and 5 on
NTDs (see Fig. 1). Among the 48 guidelines reviewed, 30 (62.5%)
were developed before the updated guidance4 on identifying
research questions in 2014.
There was considerable heterogeneity across the guidelines in
terms of research questions generated, with some disease areas
showing a higher emphasis than others on generating a set of
Fig. 1. Included guidelines by disease area. NTD ¼ neglected tropical disease; TB ¼
tuberculosis.
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process (Fig. 2). Of the 48 guidelines, 36 (75%) encompassed explicit
research questions, including 360 research questions in total: HIV,
250 (69.4%); TB, 49 (13.6%); TB-HIV, 38 (10.6%); NTDs, 23 (6.4%), and
malaria, 0 (Fig. 2). Only one guideline was identified for malaria,
which did not explicitly state any research questions. Rarely did the
guideline development groups propose an appropriate study
design to accompany a defined research question.
Distribution of research questions by category
Of the 360 research questions, the focus was on diagnosis in 43
(11.9%), prevention in 62 (17.2%), treatment in 103 (28.6%), good
practice in 12 (3.3%), service delivery in 86 (23.8), and ‘other’ in 54
(15%) questions.
There was variation in the emphasis of questions generated by
research area across the disease categories. Among the 250
research questions on HIV, the most commonly reported were
those on treatment (n ¼ 82), followed by service delivery (n ¼ 64).
Among the 49 research questions on TB, those on treatment were
also most frequently reported (n¼ 16). The main focus of the 38 TB/
HIV research questions was on service delivery (n ¼ 14), followed
by prevention (n¼ 10). The main focus of the 23 research questions
on NTDs was on prevention (n ¼ 15).
Validation of research questions
Table 1 shows the number of validated research questions. The
full data set of extracted research questions is available as
Supplementary Information. The key reasons cited by Disease Leads
as to why research questions were removed from the list of iden-
tified research questions include the following:Fig. 2. Research questions by disease area (%). NTD ¼ neglected tropical disease; TB ¼
tuberculosis.(i) The guideline from which the research question was
extracted is no longer valid.
(ii) Research questions were reframed and incorporated into a
newer guideline.
(iii) The research question is now obsolete or no longer relevant.
(iv) The research question is not well formulated.Qualitative assessment of optimum approaches
We found that research questions were commonly dispersed
across the guideline in various sections, making it difficult for the
reader to clearly see the research gaps generated by the guideline
development process. Research questions were often not formu-
lated in a specific or actionable way, with interventions not speci-
fied, study design not defined, and research questions too broad.
In many cases, guideline development groups did not specify
explicit research questions or knowledge gaps but rather opted for
paragraphs of interconnected text containing a broad discussion on
research gaps, which makes it difficult for the reader to clearly
identify the research questions. In guidelines published after the
2014 guidancedin which guideline development groups (GDGs)
were specifically asked to address the issue of research question
generationdwe found that guideline development groups began to
generate a defined section of ‘research questions,’ ‘research gaps,’
or ‘research priorities.’
We noted a number of good examples of research questions in
the cohort of guidelines that we examined, with specific and
narrowly defined questions, accompanied by recommendations
regarding study design. Examples include the following:
“Large RCTs are needed to compare the effectiveness of topical
amorolfine and butenafine in order to establish an alternative to
oral treatments for toenail infections, in both HIV-infected and the
general population.”
“Field evaluations of commercially available point-of-care tech-
nologies are needed to confirm the accuracy of results and the
strategic placement of this technology within national
programmes.”
The ‘Consolidated and Updated Guidelines on the Programmatic
Management of Latent Tuberculosis Infection’ published in 201813
was highlighted by the review team as an example of good prac-
tice in research question generation. The guideline concludes with
the research questions based on existing knowledge gaps, to sup-
port the improvement of quality of care (Table 2), with recom-
mended study designs stated.
Discussion
The cohort of guidelines on infectious diseases that we assessed
varied considerably in the extent to which they identified research
questions as part of the guideline development process. Of the
included guidelines, 75% contained explicit research questions,
most frequently focusing on disease treatment. A relevant study
design accompanying the research questions was rarely proposed.
The better examples involved the generation of specific and
narrowly defined research questions, in its own defined section of
the guideline that is easily accessible to the reader, with accom-
panying recommendations for appropriate study design.
This analysis provides evidence of the lack of a systematic
approach in identifying research questions during the guideline
development process, which is relevant to the WHO's guideline
development groups and other organizations generating guidelines
Table 1
Included guidelines and research questions after validation.
Disease area (number of guidelines and research questions)
HIV: 7 guidelines; 107 research questions
TB: 8 guidelines; 63 research questions
TB-HIV: 3 guidelines; 27 research questions
Malaria: 0
NTDs: 3 guidelines; 20 research questions
NTD ¼ neglected tropical disease; TB ¼ tuberculosis.
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knowledge gaps and actionable research questions and to present
them in WHO guidelines would add value to each guideline and to
the setting of evidence-informed public health research agendas.
This guidance could build on existing work on the generation of
research agendas through systematic reviews.14
Guidance is needed on when in the guideline process, de-
velopers should start thinking about research questions and how
reseach question formulation can be better integrated into the
guideline development process. Consideration must be given to
what expertise is needed to identify and formulate optimal ques-
tions and to the approaches that may be useful for subsequent
prioritization among these research questions.
There were limitations identified with respect to this review.
Primarily, the review team may have missed regional guidelines or
research questions within these guidelines. However workingTable 2
Research questions extracted from a WHO guideline:13 an example of good practice in r
Evidence on the risks of a number of at-risk populations for progression from LTBI to ac
and for designing appropriate public health interventions. In particular, strong evide
people with harmful use of alcohol, tobacco smokers, underweight people, people ex
conditions, indigenous populations and cancer patients.
Evidence is required on differential harm and the acceptability of testing and treatme
stigmatization.
Defining the best algorithm for ruling out active TB: Operational and clinical studies sh
performance and feasibility of the algorithms proposed in these guidelines should b
Strategies to save cost and improve feasibility (e.g. use of mobile chest radiography
The performance of LTBI tests should be evaluated in various at-risk populations, such a
and IGRA) in each at-risk population.
Research to find shorter, better-tolerated treatment regimens than those currently rec
Studies of efficacy and adverse events in certain risk groups (e.g. people who use drug
there are no or very limited data on the use of rifapentine in children <2 years and
interactions between rifamycin-containing regimens and other drugs, particularly a
The durability of protection by preventive treatment should be evaluated in settings i
treatment.
Monitoring of adverse events: Prospective randomized studies are required to determ
education and clinical observation alone for preventing severe clinical adverse even
Risk of drug resistance following LTBI treatment: Programme-based surveillance system
drugs used in LTBI treatment. Particular consideration should be given to rifamycin
Adherence to and completion of treatment: Carefully designed studies, including RCTs
interventions for enhancing adherence and completion of treatment. The studies sh
health system infrastructure. Use of “digital health” to improve adherence is an impor
the 3-month regimen of weekly rifapentine plus isoniazid.
Although a number of studies of the cost-effectiveness of TB preventive treatment are a
effectiveness of LTBI management stratified by population group and type of interven
would allow extension of the LTBI strategy at national or local level.
Preventive treatment for contacts of people with MDR-TB: RCTs with adequate power
contacts of people withMDR-TB. Trials should be performedwith both adult and paed
composition, dosage and duration of preventive treatment regimens for MDR-TB sh
properties should be investigated. The effectiveness and safety of preventive treatm
conditions. Further evidence on the risk of contacts of people with MDR-TB for prog
treatment.
Epidemiological research should be conducted to determine the burden of LTBI in vari
tailored interventions, including integrated community based approaches. Research
managed including the provision of additional interventions for tobacco smokers, illi
models could improve the effectiveness and efficiency of delivery of interventions. T
programmatic management of LTBI.
WHO ¼World Health Organization; LTBI ¼ latent tuberculosis infection; TB ¼ tuberculos
tests; RCT ¼ randomised controlled trial; MDR-TB¼ multidrug-resistant TB.directly with disease leads for each disease means that this would
have been unlikely. We are not aware of any other organizations
involved in guideline development that have analyzed and assessed
their approach to research question generation through the
guideline development process. Nor were we able to identify any
published or gray literature from other organizations on how to
generate research questions. Organizations such as the Guidelines
International Network (https://www.g-i-n.net/) may bewell placed
to strengthen approaches in generating research questions and
highlighting evidence gaps during guideline development.
This review has generated some key new considerations to
inform the standardized and systematic identification and compi-
lation of research questions for guideline development in the
future, which may be relevant to other health guideline develop-
ment groups. There should be sufficient expertise in research
among members of the guideline group to help generate researchesearch question generation.
tive disease will be crucial for determining the potential benefits of LTBI treatment
nce from clinical trials is lacking for the following groups: patients with diabetes,
posed to silica, patients receiving steroid treatment, patients with rheumatological
nt for LTBI in specific risk groups, including socially adverse events such as
ould be conducted to exclude active TB before preventive treatment is given. The
e assessed. In particular, few data are available on children and pregnant women.
) should also be explored.
s the best way of using the available tools (e.g. combination or sequential use of TST
ommended is a priority.
s, people with alcohol use disorder and elderly people) are essential. In particular,
pregnant women. Studies should be conducted of the pharmacokinetics of
ntiretroviral drugs.
n which TB is endemic, including the efficacy of repeated courses of preventive
ine the incremental benefits of routine monitoring of liver enzyme levels over
ts, with stratification of the evidence by at-risk population.
s and clinical studies are needed to monitor the risk for bacterial resistance to the
-containing regimens because of the dearth of data.
, are required to generate evidence on the effectiveness of context specific
ould include specific risk groups, depending on the available resources and the
tant area. Further research is required on the effectiveness of self administration of
vailable, their wide heterogeneity obviates a comprehensive appraisal of the cost-
tion. Direct measurement of cost-effectiveness in certain settings and populations
are urgently needed to update the recommendation on preventive treatment for
iatric populations andwith at-risk populations such as people living with HIV. The
ould be optimized, and the potential role of newer drugs with good sterilization
ent for contacts of people with MDR-TB should be evaluated in operational
ression to active TB will be important for understanding the benefits of preventive
ous geographical settings and risk groups and as a basis for nationally and locally
is also needed on service delivery models to ensure that patients are properly
cit drug users, and people with harmful use of alcohol. Household implementation
ools should be developed and assessed to facilitate monitoring and evaluation of
is; IGRA ¼ interferon gamma release assay; TB ¼ tuberculosis; TST ¼ tuberculin skin
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to guideline end users if they are short and clearly defined and in a
defined section of the published guideline.
Opportunities for the WHO to ensure the research questions
identified through its guideline development process are made
more widely available, including the compilation of an online
directory of research questions hosted by the WHO Global Obser-
vatory on Health R&D15 and presentation on the WHO website
where guidelines are published.16 Work is currently underway to
disseminate research questions using these fora.
Conclusions
This analysis shows the variable extent to which the WHO
guideline development process identifies research questions. The
results indicate the need for the WHO to strengthen its guideline
development process by systematically identifying and compiling
research questions that address key knowledge gaps. Such an
approach will facilitate the formulation of relevant and impactful
research agendas that will ultimately help to improve health pro-
grammes and achieve the Sustainable Development Goals for
health.
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